A P R I
Low probability of significant fibrosis or cirrhosis
Why This Health Metric Matters
Why: This calculation helps assess important health parameters for clinical and personal wellness tracking.
How: Enter your values above and the calculator will apply validated formulas to compute your results.
- ●Evidence-based calculations
- ●Used in clinical settings worldwide
- ●Regular monitoring recommended
🏥 Sample Clinical Scenarios
🧪 Laboratory Values
APRI Score
Clinical Interpretation
Visual Analysis
APRI Score Gauge
Risk Thresholds
Clinical Recommendations
Step-by-Step Calculation
APRI is a non-invasive marker for predicting hepatic fibrosis and cirrhosis.
AST Ratio = AST Level / AST Upper Limit
AST Ratio = 40 / 40 = 1.000
APRI = (AST Ratio / Platelet Count) × 100
APRI = (1.000 / 200) × 100
APRI = 0.500
Risk Category: Intermediate (0.5 - 1.0)
Clinical Significance: Cannot reliably rule in or rule out fibrosis
APRI Risk Categories
| Score Range | Risk Level | Description | Clinical Significance |
|---|---|---|---|
| < 0.5 | Low Risk | Low probability of significant fibrosis or cirrhosis | High negative predictive value - can rule out cirrhosis |
| 0.5 - 1.0 | Intermediate | Indeterminate zone - possible significant fibrosis | Cannot reliably rule in or rule out fibrosis |
| 1.0 - 1.5 | High Risk | Probable severe fibrosis or cirrhosis | Increased likelihood of advanced fibrosis (F3-F4) |
| > 1.5 | Very High Risk | High probability of cirrhosis | High positive predictive value - can rule in cirrhosis |
Comparing Non-Invasive Fibrosis Tests
| Test | Variables | Best For | Limitations |
|---|---|---|---|
| APRI | AST, Platelets | HCV, quick screening | Less accurate for NAFLD |
| FIB-4 | Age, AST, ALT, Platelets | NAFLD, general screening | Age affects score; gray zone common |
| NFS | Age, BMI, DM, AST/ALT, Platelets, Albumin | NAFLD specific | Complex; gray zone |
| FibroScan | Liver stiffness (kPa) | All liver diseases | Obesity may limit; requires device |
| ELF Test | Hyaluronic acid, TIMP-1, PIIINP | Advanced fibrosis detection | Cost; specialized lab |
When APRI is Most Useful
✓ Hepatitis C patients
✓ Resource-limited settings
✓ Initial screening before FibroScan
✓ Monitoring treatment response
✓ Ruling out significant fibrosis
Limitations to Consider
⚠️ Less validated for NAFLD
⚠️ Can't distinguish F2 from F3-F4
⚠️ Affected by non-liver AST sources
⚠️ Platelets affected by many conditions
⚠️ Gray zone requires further testing
<0.5
Rules out significant fibrosis
0.5-1.5
Indeterminate (gray zone)
>1.5
Likely significant fibrosis
>2.0
Likely cirrhosis
Clinical Disclaimer
APRI is a screening tool and should not replace clinical judgment. Results should be interpreted in the context of the patient's complete clinical picture. For intermediate scores, additional testing (FibroScan, ELF, or biopsy) is recommended. Always confirm fibrosis staging before major treatment decisions.
⚠️For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
— WHO
— CDC
🔬 What is the APRI Score?
The AST to Platelet Ratio Index (APRI) is a simple, non-invasive biochemical marker developed in 2003 by Dr. Chun-Tao Wai and colleagues at Virginia Commonwealth University. It predicts hepatic fibrosis and cirrhosis without requiring liver biopsy, primarily in patients with chronic hepatitis C (CHC).
APRI leverages routine laboratory parameters that reflect hepatic function changes: elevated AST indicates hepatocyte damage, while low platelet count suggests portal hypertension and splenic sequestration - hallmarks of advanced liver disease.
Key Components
- AST (Aspartate Aminotransferase): Liver enzyme elevated in hepatocyte injury; found in liver, heart, muscle
- Platelet Count: Decreases with portal hypertension and splenic sequestration in cirrhosis
- AST Upper Limit: Laboratory-specific reference value (typically 40 IU/L)
Key Studies
- • Wai CT et al. (Hepatology 2003): Original validation study - AUROC 0.80-0.88 for fibrosis prediction
- • WHO Guidelines (2014): Recommended APRI as first-line non-invasive test in resource-limited settings
- • Meta-analyses: Pooled sensitivity 77%, specificity 72% for significant fibrosis
🧮 How to Calculate APRI
- Obtain Lab Values: Get recent AST level and platelet count from comprehensive metabolic panel/CBC
- Determine AST Upper Limit: Use your lab's reference range (typically 40 IU/L)
- Calculate AST Ratio: Divide AST level by the upper limit of normal
- Apply APRI Formula: Divide AST ratio by platelet count, multiply by 100
- Interpret Results: Compare score to threshold values for fibrosis staging
APRI Formula:
APRI = [(AST / AST Upper Limit) / Platelet Count (10⁹/L)] × 100
Clinical Pearl
The formula essentially captures the ratio of liver injury (AST elevation) to portal hypertension (thrombocytopenia). In cirrhosis, AST tends to rise while platelets fall due to decreased thrombopoietin production and splenic sequestration.
⏰ When to Use APRI
Clinical Applications
- Chronic hepatitis C fibrosis staging
- Hepatitis B fibrosis assessment
- Initial screening before liver biopsy
- Monitoring disease progression over time
- Resource-limited settings (WHO recommended)
- Serial monitoring post-treatment
Limitations
- Intermediate values (0.5-1.5) require further testing
- Less accurate for mild/moderate fibrosis (F1-F2)
- Affected by non-hepatic AST elevation (muscle injury)
- Platelet count affected by other conditions (ITP, drugs)
- Not validated for alcoholic liver disease
- Consider FIB-4 or FibroScan for indeterminate results
AASLD/EASL Guidelines
Both American and European liver associations recommend using non-invasive tests like APRI and FIB-4 as initial assessment before considering liver biopsy. APRI < 0.5 reliably excludes cirrhosis; APRI > 1.5 strongly suggests it.
📐 APRI Scoring Thresholds
| APRI Score | Interpretation | Sensitivity/Specificity | METAVIR Stage |
|---|---|---|---|
| < 0.5 | Rule out significant fibrosis | High NPV (~90%) | F0-F1 |
| 0.5 - 0.7 | Possible fibrosis - indeterminate | Consider additional testing | F1-F2 |
| 0.7 - 1.0 | Significant fibrosis threshold | 77% sens / 72% spec | F2 |
| 1.0 - 1.5 | Probable severe fibrosis | 61-76% sens / 64-72% spec | F3 |
| > 1.5 | Rule in cirrhosis | High PPV (~90%) | F4 |
📚 Clinical Decision Algorithm
Recommended Workflow for Chronic Hepatitis C
- Calculate APRI as first-line screening test
- If APRI < 0.5: Low risk - routine monitoring, repeat in 1-2 years
- If APRI 0.5-1.5: Indeterminate - obtain FIB-4 or FibroScan for further stratification
- If APRI > 1.5: High risk - assume significant fibrosis, initiate HCV treatment, screen for varices and HCC
- Consider liver biopsy if non-invasive tests discordant or for specific indications (autoimmune features, etc.)